---
figid: PMC6770909__cancers-11-01382-g001
figlink: /pmc/articles/PMC6770909/figure/cancers-11-01382-f001/
number: F1
caption: Redifferentiation of thyroid cancer. MAPK (mitogen-activated protein kinase)
  (RAS/RAF/MEK) and PI3K/AKT/mTOR are key signaling pathways in thyroid cancer pathogenesis.
  Signaling cascades can be blocked by new targeted therapies. The crosstalk between
  MAPK and PI3K through RAS is shown and represents a tumor escape mechanism from
  known multi-kinase inhibitors and selective inhibitors of BRAF. PI3K-AKT pathway
  activation leads to suppression of NIS (sodium/iodide symporter) glycosylation and
  surface translocation. The inhibition of mTOR promotes redifferentiation of thyroid
  cancer cells by upregulation of NIS mRNA and protein expression through increased
  transcription of TTF1. Another important positive regulator of NIS expression is
  PTEN. TSH (thyroid stimulating hormone) signals through the heterotrimeric G-protein
  complex, and through activation of cAMP increases transcription of the NIS gene.
  Aberrant activation of the MAPK signaling pathway inhibits PIGU expression and NIS
  basolateral transport. PTTG1 and PBF overexpression results in decreased NIS levels
  in thyroid cancer.
pmcid: PMC6770909
papertitle: 'Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation
  Therapies, Management, and Novel Therapies.'
reftext: Mohamed Aashiq, et al. Cancers (Basel). 2019 Sep;11(9):1382.
pmc_ranked_result_index: '18047'
pathway_score: 0.9692508
filename: cancers-11-01382-g001.jpg
figtitle: Redifferentiation of thyroid cancer
year: '2019'
organisms:
- Rattus norvegicus
- Homo sapiens
ndex: db541eb9-dec8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6770909__cancers-11-01382-g001.html
  '@type': Dataset
  description: Redifferentiation of thyroid cancer. MAPK (mitogen-activated protein
    kinase) (RAS/RAF/MEK) and PI3K/AKT/mTOR are key signaling pathways in thyroid
    cancer pathogenesis. Signaling cascades can be blocked by new targeted therapies.
    The crosstalk between MAPK and PI3K through RAS is shown and represents a tumor
    escape mechanism from known multi-kinase inhibitors and selective inhibitors of
    BRAF. PI3K-AKT pathway activation leads to suppression of NIS (sodium/iodide symporter)
    glycosylation and surface translocation. The inhibition of mTOR promotes redifferentiation
    of thyroid cancer cells by upregulation of NIS mRNA and protein expression through
    increased transcription of TTF1. Another important positive regulator of NIS expression
    is PTEN. TSH (thyroid stimulating hormone) signals through the heterotrimeric
    G-protein complex, and through activation of cAMP increases transcription of the
    NIS gene. Aberrant activation of the MAPK signaling pathway inhibits PIGU expression
    and NIS basolateral transport. PTTG1 and PBF overexpression results in decreased
    NIS levels in thyroid cancer.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB3
  - MAP2K1
  - MAP2K2
  - ERBB2
  - AKT3
  - AKT1
  - AKT2
  - BRAF
  - MAPK1
  - MAPK3
  - GNAL
  - GNAS
  - TTF1
  - FLT4
  - FLT1
  - KDR
  - PRKAR2B
  - MTOR
  - PAX8
  - PDGFRA
  - PDGFRB
  - PIK3R6
  - PIK3R5
  - RET
  - TSHR
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIGU
  - PRKAR1A
  - PRKACA
  - PRKACB
  - PRKACG
  - PTTG1
  - PRKAR1B
  - PRKAR2A
  - PTEN
  - NRAS
  - HRAS
  - KRAS
  - PIK3R4
  - PIK3CA
  - PIK3CB
  - Sulfatinib
  - Vandetanib
  - Na
  - Lapatinib
  - Sorafenib
  - Lenvatinib
  - Dabrafenib
  - Vemurafenib
  - Selumetinib
  - Temsirolimus
  - Trametinib
  - Everolimus
  - Cancer
  - Lung cancer
genes:
- word: HER2/3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: HER2/3
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Gs
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAL
  entrez: '2774'
- word: Gs
  symbol: Gs
  source: bioentities_symbol
  hgnc_symbol: GNAS
  entrez: '2778'
- word: (TTF1)
  symbol: TTF1
  source: hgnc_symbol
  hgnc_symbol: TTF1
  entrez: '7270'
- word: (VEGFR,
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: (VEGFR,
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: (VEGFR,
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2B
  entrez: '5577'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PAX8
  symbol: PAX8
  source: hgnc_symbol
  hgnc_symbol: PAX8
  entrez: '7849'
- word: PDGFR,RET)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: PDGFR,RET)
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: RET)
  symbol: RET
  source: hgnc_symbol
  hgnc_symbol: RET
  entrez: '5979'
- word: TSHR
  symbol: TSHR
  source: hgnc_symbol
  hgnc_symbol: TSHR
  entrez: '7253'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PIGU
  symbol: PIGU
  source: hgnc_symbol
  hgnc_symbol: PIGU
  entrez: '128869'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1A
  entrez: '5573'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACA
  entrez: '5566'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACB
  entrez: '5567'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKACG
  entrez: '5568'
- word: PTTG1
  symbol: PTTG1
  source: hgnc_symbol
  hgnc_symbol: PTTG1
  entrez: '9232'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR1B
  entrez: '5575'
- word: PKA
  symbol: PKA
  source: bioentities_symbol
  hgnc_symbol: PRKAR2A
  entrez: '5576'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
chemicals:
- word: Sulfatinib
  source: ''
  identifier: ''
- word: Vandetanib
  source: MESH
  identifier: C452423
- word: Na
  source: MESH
  identifier: D012964
- word: Lapatinib
  source: MESH
  identifier: C490728
- word: Sorafenib
  source: MESH
  identifier: C471405
- word: Lenvatinib
  source: MESH
  identifier: C531958
- word: Dabrafenib
  source: MESH
  identifier: C561627
- word: Vemurafenib
  source: MESH
  identifier: C551177
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Everolimus
  source: MESH
  identifier: C107135
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
figid_alias: PMC6770909__F1
redirect_from: /figures/PMC6770909__F1
figtype: Figure
---
